This year, FERO will contribute €200,000, with which it will seek to provide structural and sustained support for the Molecular Diagnostics Programme1
These awards are organized by the Spanish Metastatic Breast Cancer Association to promote research in this area. The project presented by Dr. Aleix1
Sexual health is an important part of anyone's life and has an impact on their overall health. Often, when a person is suffering from a disease, it a1
HER2DX® was highlighted in Times 'Medical Care' category, which publicizes inventions that are successfully implemented in medical practice.
Both imaging techniques detect breast lesions, but have differences between them.
Trial TILs001, which is open to patients with metastatic triple-negative breast cancer, is the first study to assess the safety and efficacy of TILs1
Treatment with trastuzumab deruxtecan, a combination of a targeted therapy with chemotherapy, increases progression-free survival of the disease and1
The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.
In a study published in the Journal of Clinical Oncology, researchers from the Hospital Clínic-IDIBAPS-UB and SOLTI showed the predictive capacity of1
